AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie ubrelvy (ubrogepant) — International reported growth YoY (%) (%)
Form 8-K Key Product Revenues Schedule
Latest, Q2 2026
54.9%
Period ended Jun 30, 2026
Change on a year earlier
-19.0 pts
73.9% in Q2 2025
History
8 quarters
Since Q2 2024
Sources
8
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Ubrelvy (ubrogepant) — International reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 54.9% | -19.0 pts | Form 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗ |
| Q1 2026 | Mar 31, 2026 | 29.2% | +5.9 pts | Form 8-K (abbv-20260331xexhibit991.htm, filed 2026-04-29) ↗ |
| Q4 2025 | Dec 31, 2025 | -3.7% | -69.0 pts | Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗ |
| Q3 2025 | Sep 30, 2025 | 34.1% | – | Form 8-K (abbv-20250930xexhibit991.htm, filed 2025-10-31) ↗ |
| Q2 2025 | Jun 30, 2025 | 73.9% | -7.7 pts | Form 8-K (abbv-20250630xexhibit991.htm, filed 2025-07-31) ↗ |
| Q1 2025 | Mar 31, 2025 | 23.3% | – | Form 8-K (abbv-20250331xexhibit991.htm, filed 2025-04-25) ↗ |
| Q4 2024 | Dec 31, 2024 | 65.3% | – | Form 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗ |
| Q2 2024 | Jun 30, 2024 | 81.6% | – | Form 8-K (abbv-20240630xexhibit991.htm, filed 2024-07-25) ↗ |
Cite this data
StockData. (2026). AbbVie Ubrelvy (ubrogepant) — International reported growth YoY (%) (%), quarterly Q2 2024–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/ubrelvy_intl_rep_yoy
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.